Navigation Links
Dermagen Reports Successful Phase I/IIa Clinical Trial for Atopic Dermatitis
Date:12/2/2009

LUND, Sweden, December 2 /PRNewswire/ -- DermaGen AB - part of the Karolinska Development dermatology and wound healing company "Pergamum" - today announced that Dermagen AB has received promising results from a clinical Phase I/IIa study. DermaGen AB is developing a novel antimicrobial peptide (AMP) treatment for atopic dermatitis. Atopic dermatitis is a chronic inflammatory skin disease where dry skin and the skin's weakened barrier function make patients susceptible to colonization by microorganisms, a triggering or exacerbating factor of the disease. The AMP has shown a broad spectrum of activity and is both bactericidal and fungicidal. In the clinical trial, the company's candidate drug clearly reached its primary objective, demonstrating a significant reduction of total microbes in eczemas compared to placebo. In addition to good safety and tolerability performance, the candidate drug also showed a trend towards improved eczema status. This is the first time a study has shown efficacy of AMPs for atopic dermatitis in man.

Commenting on the study, DermaGen's Managing Director, Jan Alenfall, said, "Achieving such promising results from a first-time-in-man trial is very pleasing. The observed trend towards improvement of the disease condition provides particular encouragement. We will now initiate further clinical studies to substantiate this. Skin infection is recognized as an aggravating factor of atopic dermatitis. The development of a new class of treatment, capable of eradicating microbes with limited risk of microbial resistance development, is likely to have significant market appeal within this and other dermatological indications."

Jorgen Thorball, Pergamum's Chairman, stated, "DermaGen is a very exciting company with a strong technology platform. These promising clinical results go a long way towards establishing proof of concept within atopic dermatitis. They also strengthen the company's po
'/>"/>

SOURCE DermaGen AB
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. DermaGen AB Receives Over 1 Million Euros From a New Share Issue
2. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
3. Spherix Reports Second Quarter Earnings
4. Tapestry Reports Second Quarter 2007 Results
5. Callisto Reports on Second-Quarter 2007 Milestones
6. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
7. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
8. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
9. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
10. Biopure Reports on Meeting with the FDA
11. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... INDIANAPOLIS and LYON, France ... (NYSE: LLY ) and Adocia (Euronext Paris: ... focused on developing an ultra-rapid insulin, known as BioChaperone ... type 2 diabetes. BioChaperone Lispro relies on Adocia,s proprietary ... Lilly and Adocia will develop BioChaperone Lispro ...
(Date:12/17/2014)... , Dec. 17, 2014 Royal Philips ... Corporation (NASDAQ: VOLC ), a global leader in ... that they have entered into a definitive merger agreement. Pursuant ... acquire all of the issued and outstanding shares of Volcano ... price of USD 1 billion (approx. EUR 800 million), to ...
(Date:12/17/2014)... -- Revenue and earnings above the previous year ... In the past 2013/14 fiscal year (ended 30 ... EUR 4.287 billion (last year: EUR 4.190 billion) despite unfavorable ... 360 million. "Overall, 2013/14 was a successful fiscal year for ... and CEO of Carl Zeiss AG. "Thanks to our broad ...
Breaking Medicine Technology:Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 2Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 3Philips to acquire Volcano to expand global leadership position in image-guided therapy market 2Philips to acquire Volcano to expand global leadership position in image-guided therapy market 3Philips to acquire Volcano to expand global leadership position in image-guided therapy market 4Philips to acquire Volcano to expand global leadership position in image-guided therapy market 5Philips to acquire Volcano to expand global leadership position in image-guided therapy market 6Philips to acquire Volcano to expand global leadership position in image-guided therapy market 7Philips to acquire Volcano to expand global leadership position in image-guided therapy market 8ZEISS Asserts its Position in Difficult Environment 2
... May 21, 2007/PRNewswire-FirstCall/ -- Bristol-Myers,Squibb Company (NYSE: ... which showed that treatment with Baraclude (entecavir),demonstrated ... 48 weeks,-- a result that was also ... These data from an open-label, randomized viral ...
... -- Data presented,today at a major medical meeting ... for five days is as,effective as standard therapy ... treatment of complicated urinary tract infections,(cUTI) and acute ... markets LEVAQUIN in the,U.S., presented the data during ...
Cached Medicine Technology:Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 2Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 3Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 4Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 5Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 6Five Days of LEVAQUIN(R) as Effective as 10 Days of Ciprofloxacin,in Complicated Urinary Tract Infections and Acute Pyelonephritis 2Five Days of LEVAQUIN(R) as Effective as 10 Days of Ciprofloxacin,in Complicated Urinary Tract Infections and Acute Pyelonephritis 3Five Days of LEVAQUIN(R) as Effective as 10 Days of Ciprofloxacin,in Complicated Urinary Tract Infections and Acute Pyelonephritis 4
(Date:12/21/2014)... 2014 Recently, one of the best ... Prom Shop has introduced its new collection of ... big discounts on all its prom dresses & other ... insists on providing top quality dress products and great ... considered as one of the best prom dresses online ...
(Date:12/21/2014)... Mi (PRWEB) December 21, 2014 AlignLife ... child in need while at the same time helping people ... is a non-profit community-based organization committed to serving those persons ... meet their needs to improve the quality of life. Dr. ... make an impact in the local community and he knew ...
(Date:12/21/2014)... AZ (PRWEB) December 21, 2014 Parker ... range of heating, cooling, plumbing and other similar home ... in 2014 with regard to its expert contracting services. ... industry leader that has been serving Arizona for well ... in providing the absolute best in quality customer service ...
(Date:12/21/2014)... OR (PRWEB) December 21, 2014 ... some of the issues and systemic barriers for disabled ... World Paratriathlon Champion. Scheidies has a condition called juvenile ... time. He describes how he adapted his athletic ambitions ... use his success in triathlon to pioneer the way ...
(Date:12/21/2014)... As testosterone therapy lawsuit filings ... blood clots from using testosterone products such as AndroGel ... that the male hormone testosterone may increase the risk ... in the Proceedings of the National Academy of Sciences ... of male rats with naturally occurring colon cancer. Dr. ...
Breaking Medicine News(10 mins):Health News:New Prom Dresses From One Of The Best Prom Dresses Online Shops, LunaDress Prom Shop 2Health News:AlignLife of Norton Shores Makes a Brighter Christmas for Kids in Muskegon 2Health News:Parker & Sons Announces Record Number Of Favorable Reviews In 2014 With Regard To Its Expert Contracting Services 2Health News:Parker & Sons Announces Record Number Of Favorable Reviews In 2014 With Regard To Its Expert Contracting Services 3Health News:Disability in Sports on SCI TV with Triathlon World Champ Aaron Scheidies 2Health News:Disability in Sports on SCI TV with Triathlon World Champ Aaron Scheidies 3Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 2Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 3Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 4
... have announced the discovery of another gene responsible for ... of the disease (occurring in around 90 percent of ... from Boston University, the University of Toronto, and Columbia ... published in Nature Genetics. ,The reasearchers ...
... Natalia Trayanova's research team works on understanding the ... the Computational Cardiac Electrophysiology Lab, //she is a ... ,The subtle rhythms, pulses and patterns of ... scientists alike for millennia, yet the heart's deepest ...
... sun exposure may differ across Australia, a senior cancer researcher ... needed for the production of vitamin D, which is necessary ... for prevention of several cancers. ,Australians are ... keeping out of the sun to avoid skin cancer and ...
... school research project, titled 'Sun Safe in the Middle School ... of "Pediatrics”, was undertaken to stress the importance of educating ... using sun protection as a tool to offset the risk ... , ,It is observed that maximum sun exposure happens ...
... use during pregnancy can cause subtle but disabling ... emotional problems //– Says a recent study by ... Vanderbilt Kennedy Center for Research on Human Development ... problems associated with prenatal exposure to cocaine. In ...
... for cancer has sprung from an inconspicuous mushroom that cannot ... of its promise, are getting ready to conduct clinical trials ... be a possible treatment for cancer. ,The ... China and Japan, where it has helped increase life expectancy, ...
Cached Medicine News:Health News:New Gene to Help in Understanding Alzheimer’s Diseas 2Health News:Secrets of the Heart's Signals 2Health News:Safe Sun Exposure a Burning Issue 2Health News:Cocaine's Use During Pregnancy May Cause Lasting Cellular Effects 2Health News:Cocaine's Use During Pregnancy May Cause Lasting Cellular Effects 3
... tip is specially rounded, extra ... wound and manipulation in the ... flexible tubing 25cm, ID - ... annular rings start .85mm ...
For administering anesthetic agents into the posterior sub-Tenon's space 20G x 1in (.90 x 25mm)...
... This all digital single plane C-arm angiography ... cardiac imaging performance and an expansive range ... cardiac angiography to ECG triggered. ... Detector technology,State of the art dynamic Flat ...
For diagnostic and operative treatment of hand and wrist bones. The use of this distraction device allows fracture reduction or widening of the space between bones....
Medicine Products: